XML 64 R30.htm IDEA: XBRL DOCUMENT v3.20.1
DESCRIPTION OF BUSINESS (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2018
patient
Sep. 30, 2016
USD ($)
shares
Mar. 31, 2020
USD ($)
segment
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Variable Interest Entity [Line Items]          
Number of patients | patient 133        
Number of Operating Segments | segment     1    
Cash and cash equivalents     $ 42,463   $ 48,121
Net working capital     37,500    
Accumulated deficit     251,960   293,524
Negative cash flows from operating activities incurred     $ 8,838 $ 7,992 $ 37,500
Viventia Bio, Inc.          
Variable Interest Entity [Line Items]          
Shares of common stock issued to the selling shareholders (in shares) | shares   4,000,000.0      
Percentage of voting interests acquired (as a percent)   19.90%      
One-time milestone payment upon first sale of product   $ 12,500      
Period during which quarterly earn-outs are payable after date of net sales   15 years      
Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations   7 years      
Viventia Bio, Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone          
Variable Interest Entity [Line Items]          
Percentage of net sales of quarterly earn-out payments during earn-out periods   2.00%      
Viventia Bio, Inc. | Vicinium | Europe | Collaborative Arrangement, Revenue based on Specified Milestone          
Variable Interest Entity [Line Items]          
One-time milestone payment upon first sale of product   $ 7,000      
Viventia Bio, Inc. | Vicinium | Japan | Collaborative Arrangement, Revenue based on Specified Milestone          
Variable Interest Entity [Line Items]          
One-time milestone payment upon first sale of product   $ 3,000